Prof. Dr. Rainer Riedl

Work at ZHAW

Position

• Head of Competence Center for Drug Discovery
• Head of Organic and Medicinal Chemistry

Network

Membership of networks

• Swiss Academy of Engineering Sciences SATW
• Biotechnet Switzerland
• German Academic Scholarship Foundation
• Swiss Chemical Society
• Alexander von Humboldt Foundation

ORCID digital identifier

ORCID ID: 0000-0003-2534-1963

Social media

linkedin

Projects

• Targeting the innate immune system for Multiple Sclerosis / Project leader / ongoing
• Alzheimer's dementia / Project leader / ongoing
• Small molecules targeting CD93-signaling for the treatment of acute myeloid leukemia / Project leader / ongoing
• Peptidic active ingredients III / Project leader / completed
• Evaluation of the potential of PROTACs / Project leader / completed
• Peptidic active ingredients II / Project leader / completed
• Targeting Gram-negative bacteria / Project leader / completed
• Innovative Immunotherapy Approach / Project leader / completed
• Synthesis of peptidic active ingredients / Project leader / completed
• Therapy for the NRAS melanoma subtype / Project leader / completed
• Platform for drug target identification / Project leader / completed
• Inhibitors targeting SARS-CoV-2 proteases / Project leader / completed
• Extracellular vesicles for targeted delivery of new antimicrobials / Deputy project leader / completed
• Developing novel and effective therapies for treatment of childhood brain cancers / Project leader / completed
• Development of new therapeutic approaches for the treatment of cancer / Project leader / completed
• Developing a gasotransmitter based treatment for pathological skin and tendon calcification / Project leader / completed
• Plants and Minerals in Byzantine Popular Pharmacy. A New Multidisciplinary Approach / Deputy project leader / completed
• Development of small-molecules targeting CD93-signaling for the treatment of leukemia / Project leader / completed
• Inflammasome inhibitors - Development of new inhibitors / Project leader / completed
• Burn Wound Treatment / Project leader / completed
• Silent pathway awakening to discover novel antibacterial compounds from actinomycetes / Deputy project leader / completed
• A topical anti-infective / Project leader / completed
• Morbillivirus cell entry machinery: mechanisms, structures and antiviral drug discovery / Co-project leader / completed
• Identification and characterization of active substances from actinomycetes from Switzerland against pathogenic bacteria / Project leader / completed
• Virus cell entry machinery: antiviral drug discovery / Project leader / completed
• Novel Antimicrobials for Life-Threatening Infections / Project leader / completed
• Dynamic combinatorial chemistry in drug discovery / Project leader / completed
• New antileishmanial and antitrypanosomal drugs / Project leader / completed
• New drugs for the treatment of protozoal infections derived from natural products / Project leader / completed
• Development of high temperature resistant, synergistic biocidal products for protection of PVC against microbial infestation for commercial product applications / Project leader / completed
• HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increases antibiotic susceptibility of multidrug resistant staphylococci / Project leader / completed
• Research and development in the field of potential small molecule drugs against diabetes / Project leader / completed
• Prevention of undesired interactions between biocides and additives in synthetic materials to improve efficacy and to reduce the necessary amount of biocides / Project leader / completed
• Development of a software to analyse chemical and biological data: CyBy2 / Project leader / completed
• HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic / Project leader / completed
• Identification of novel targets and drug candidates against multi-drug resistant bacteria / Project leader / completed

Publications

Articles in scientific journal, peer-reviewed

• Scherer, M., Djabeur, N., Siering, O., Jeckelmann, J.-M., Wyss, M., Cresci, M., Di Palma Subran, M., Riedl, R., Chames, P., Pfaller, C. K., Sawatsky, B., Fotiadis, D., & Plattet, P. (2026). Protection against lethal canine distemper virus infection by a dual epitope-targeting synthetic antibody. Nature Communications, 17(1), 103. https://doi.org/10.1038/s41467-025-67600-z
• Nasi, S., Ehirchiou, D., Blatter, C., Chobaz, V., Germann, S., Brandenberger, A., Bommeli, E., Uchikawa, E., Cirino, G., Riedl, R., So, A., & Busso, N. (2025). Allosteric activators of cystathionine γ lyase to augment endogenous hydrogen sulfide and inhibit pathologic calcification. Pharmacological Research, 219(107869). https://doi.org/10.1016/j.phrs.2025.107869
• Rimle, L., Pliatsika, D., Arnold, N., Kurth, S., Kaiser, M., Mäser, P., Kemmler, M., Adams, M., Riedl, R., & von Ballmoos, C. (2025). Dissecting structural requirements of leucinostatin A derivatives for antiprotozoal activity and mammalian toxicity. Journal of Medicinal Chemistry, 68(4), 4237–4258. https://doi.org/10.1021/acs.jmedchem.4c01989
• Fischer, T., Frasson, D., Sievers, M., & Riedl, R. (2024). Phthalimide derivatives as a new class of papain-like protease inhibitors in SARS-CoV-2. Archiv Der Pharmazie, 358(1), e2400714. https://doi.org/10.1002/ardp.202400714
• Fischer, T., Frasson, D., Sievers, M., & Riedl, R. (2024). Phthalimide derivatives as a new class of papain‐like protease inhibitors in SARS‐CoV‐2. Archiv Der Pharmazie, 358(1), e2400714. https://doi.org/10.1002/ardp.202400714
• Pliatsika, D., Blatter, C., & Riedl, R. (2024). Targeted protein degradation : current molecular targets, localization, and strategies. Drug Discovery Today, 29(11), 104178. https://doi.org/10.1016/j.drudis.2024.104178
• Kalbermatter, D., Jeckelmann, J.-M., Wyss, M., Shrestha, N., Pliatsika, D., Riedl, R., Lemmin, T., Plattet, P., & Fotiadis, D. (2023). Structure and supramolecular organization of the canine distemper virus attachment glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 120(6), e2208866120. https://doi.org/10.1073/pnas.2208866120
• Sabani, B., Brand, M., Albert, I., Inderbitzin, J., Eichenseher, F., Schmelcher, M., Rohrer, J., Riedl, R., & Lehmann, S. (2023). A novel surface functionalization platform to prime extracellular vesicles for targeted therapy and diagnostic imaging. Nanomedicine: Nanotechnology, Biology and Medicine, 47(102607). https://doi.org/10.1016/j.nano.2022.102607
• Bagatella, S., Haghayegh Jahromi, N., Monney, C., Polidori, M., Gall, F. M., Marchionatti, E., Serra, F., Riedl, R., Engelhardt, B., & Oevermann, A. (2022). Bovine neutrophil chemotaxis to Listeria monocytogenes in neurolisteriosis depends on microglia-released rather than bacterial factors. Journal of Neuroinflammation, 19(304). https://doi.org/10.1186/s12974-022-02653-1
• Kiss, C., Gall, F. M., Dreier, B., Adams, M., Riedl, R., Plückthun, A., & Mittl, P. R. E. (2022). Structure of a hydrophobic leucinostatin derivative determined by host lattice display. Acta Crystallographica. Section D: Structural Biology, 78(12), 1439–1450. https://doi.org/10.1107/S2059798322010762
• Brand, M., Bommeli, E. B., Rütimann, M., Lindenmann, U., & Riedl, R. (2022). Discovery of a dual SENP1 and SENP2 inhibitor. International Journal of Molecular Sciences, 23(20), 12085. https://doi.org/10.3390/ijms232012085
• Fischer, T., & Riedl, R. (2022). Paracelsus’ legacy in the faunal realm : drugs deriving from animal toxins. Drug Discovery Today, 27(2), 567–575. https://doi.org/10.1016/j.drudis.2021.10.003
• Shrestha, N., Gall, F. M., Mathieu, C., Hierweger, M. M., Brügger, M., Alves, M. P., Vesin, J., Banfi, D., Kalbermatter, D., Horvat, B., Chambon, M., Turcatti, G., Fotiadis, D., Riedl, R., & Plattet, P. (2021). Highly potent host-specific small-molecule inhibitor of paramyxovirus and pneumovirus replication with high resistance barrier. mBio, 12(6), e0262121. https://doi.org/10.1128/mBio.02621-21
• Neidhart, B., Kowalska, M., Valentin, J. D. P., Gall, F., Ren, Q., Riedl, R., Pot, S., & Rottmar, M. (2021). Tissue inhibitor of metalloproteinase (TIMP) peptidomimetic as an adjunctive therapy for infectious keratitis. Biomacromolecules, 22(2), 629–639. https://doi.org/10.1021/acs.biomac.0c01473
• Brand, M., Wang, L., Agnello, S., Gazzola, S., Gall, F., Raguž, L., Kaiser, M., Schmidt, R. S., Ritschl, A., Jelk, J., Hemphill, A., Mäser, P., Bütikofer, P., Adams, M., & Riedl, R. (2021). Antiprotozoische Struktur‐Aktivitäts‐Beziehungen von synthetischen Leucinostatin‐Derivaten und Aufklärung ihres Wirkprinzips. Angewandte Chemie, 133(28), 15741–15749. https://doi.org/10.1002/ange.202102153
• Brand, M., Wang, L., Agnello, S., Gazzola, S., Gall, F., Raguž, L., Kaiser, M., Schmidt, R. S., Ritschl, A., Jelk, J., Hemphill, A., Mäser, P., Bütikofer, P., Adams, M., & Riedl, R. (2021). Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action. Angewandte Chemie: International Edition, 60(28), 15613–15621. https://doi.org/10.1002/anie.202102153
• Zizzari, A. T., Pliatsika, D., Gall, F., Fischer, T., & Riedl, R. (2021). New perspectives in oral peptide delivery. Drug Discovery Today, 26(4), 1097–1105. https://doi.org/10.1016/j.drudis.2021.01.020
• Shrestha, N., Gall, F., Vesin, J., Chambon, M., Turcatti, G., Fotiadis, D., Riedl, R., & Plattet, P. (2021). Antiviral screen against canine distemper virus-induced membrane fusion activity. Viruses, 13(1), 128. https://doi.org/10.3390/v13010128
• Arn, F., Frasson, D., Kroslakova, I., Rezzonico, F., Pothier, J., Riedl, R., & Sievers, M. (2020). Isolation and identification of actinomycetes strains from Switzerland and their biotechnological potential. Chimia, 74(5), 382–390. https://doi.org/10.2533/chimia.2020.382
• Fischer, T., & Riedl, R. (2020). Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Expert Opinion on Drug Discovery, 16(1), 75–88. https://doi.org/10.1080/17460441.2020.1819235
• Kalbermatter, D., Shrestha, N., Gall, F., Wyss, M., Riedl, R., Plattet, P., & Fotiadis, D. (2020). Cryo-EM structure of the prefusion state of canine distemper virus fusion protein ectodomain. Journal of Structural Biology: X, 4, 100021. https://doi.org/10.1016/j.yjsbx.2020.100021
• Lindenmann, U., Brand, M., Gall, F., Frasson, D., Hunziker, L., Kroslakova, I., Sievers, M., & Riedl, R. (2020). Discovery of a class of potent and selective non‐competitive sentrin‐specific protease 1 inhibitors. ChemMedChem, 15(8), 675–679. https://doi.org/10.1002/cmdc.202000067
• Fischer, T., Koulas, S. M., Tsagkarakou, A. S., Kyriakis, E., Stravodimos, G. A., Skamnaki, V. T., Liggri, P. G. V., Zographos, S. E., Riedl, R., & Leonidas, D. D. (2019). High consistency of structure-based design and x-ray crystallography : design, synthesis, kinetic evaluation and crystallographic binding mode determination of biphenyl-N-acyl-β-D-glucopyranosylamines as glycogen phosphorylase inhibitors. Molecules, 24(7), 1322. https://doi.org/10.3390/molecules24071322
• Fischer, T., & Riedl, R. (2019). Inhibitory antibodies designed for matrix metalloproteinase modulation. Molecules, 24(12), 2265. https://doi.org/10.3390/molecules24122265
• Höck, S., & Riedl, R. (2019). CyBy2 : a strongly typed, purely functional framework for chemical data management. Journal of Cheminformatics, 11(80). https://doi.org/10.1186/s13321-019-0403-2
• Fischer, T., Gazzola, S., & Riedl, R. (2019). Approaching target selectivity by de novo drug design. Expert Opinion on Drug Discovery, 14(8), 791–803. https://doi.org/10.1080/17460441.2019.1615435
• Fischer, T., Senn, N., & Riedl, R. (2019). Design and structural evolution of matrix metalloproteinase inhibitors. Chemistry – A European Journal, 25(34), 7960–7980. https://doi.org/10.1002/chem.201805361
• Gall, F., Hohl, D., Frasson, D., Wermelinger, T., Mittl, P. R. E., Sievers, M., & Riedl, R. (2019). Drug design inspired by nature : crystallographic detection of an auto‐tailored protease inhibitor template. Angewandte Chemie: International Edition, 58(12), 4051–4055. https://doi.org/10.1002/anie.201812348
• Gall, F., Hohl, D., Frasson, D., Wermelinger, T., Mittl, P. R. E., Sievers, M., & Riedl, R. (2019). Von der Natur inspiriertes Wirkstoffdesign : kristallographische Detektion eines selbstgenerierten Inhibitor‐Grundgerüsts. Angewandte Chemie, 131(12), 4091–4096. https://doi.org/10.1002/ange.201812348
• Kalbermatter, D., Shrestha, N., Ader-Ebert, N., Herren, M., Moll, P., Plemper, R. K., Altmann, K.-H., Langedijk, J. P., Gall, F., Lindenmann, U., Riedl, R., Fotiadis, D., & Plattet, P. (2018). Primary resistance mechanism of the canine distemper virus fusion protein against a small-molecule membrane fusion inhibitor. Virus Research, 259, 28–37. https://doi.org/10.1016/j.virusres.2018.10.003
• Agnello, S., Brand, M., Chellat, M., Gazzola, S., & Riedl, R. (2018). A Structural view on medicinal chemistry strategies against drug resistance. Angewandte Chemie, 58(11), 3300–3345. https://doi.org/10.1002/anie.201802416
• Agnello, S., Brand, M., Chellat, M., Gazzola, S., & Riedl, R. (2018). Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. Angewandte Chemie, 131(11), 3336–3383. https://doi.org/10.1002/ange.201802416
• Fischer, T., & Riedl, R. (2017). Cover profile : targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor. ChemistryOpen, 6(2), 167. https://doi.org/10.1002/open.201700042
• Chellat, M. F., & Riedl, R. (2017). Pseudouridimycin : das erste Nukleosid-Analogon, das bakterielle RNA-Polymerase selektiv inhibiert. Angewandte Chemie, 129(43), 13364–13366. https://doi.org/10.1002/ange.201708133
• Fischer, T., & Riedl, R. (2017). Cover picture : targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor (ChemistryOpen 2/2017). ChemistryOpen, 6(2), 165. https://doi.org/10.1002/open.201700043
• Fischer, T., & Riedl, R. (2017). Development of a non-hydroxamate dual matrix metalloproteinase (MMP)-7/-13 inhibitor. Molecules, 22(9). https://doi.org/10.3390/molecules22091548
• Abu Eid, S., Adams, M., Scherer, T., Torres-Gómez, H. M., Hackl, M. T., Kaplanian, M., Riedl, R., Luger, A., & Fürnsinn, C. (2017). Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents. European Journal of Pharmacology, 798, 77–84. https://doi.org/10.1016/j.ejphar.2017.01.022
• Fischer, T., & Riedl, R. (2017). Targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor. ChemistryOpen, 6(2), 192–195. https://doi.org/10.1002/open.201600158
• Chellat, M. F., & Riedl, R. (2017). Pseudouridimycin : the first nucleoside analogue that selectively inhibits bacterial RNA polymerase. Angewandte Chemie: International Edition, 56(43), 13184–13186. https://doi.org/10.1002/anie.201708133
• Senn, N., Ott, M., Lanz, J., & Riedl, R. (2017). Targeted polypharmacology : discovery of a highly potent non-hydroxamate dual matrix metalloproteinase (MMP)-10/-13 inhibitor. Journal of Medicinal Chemistry, 60(23), 9585–9598. https://doi.org/10.1021/acs.jmedchem.7b01001
• Fischer, T., & Riedl, R. (2016). Molecular recognition of the catalytic zinc(II) ion in MMP-13 : structure-based evolution of an allosteric inhibitor to dual binding mode inhibitors with improved lipophilic ligand efficiencies. International Journal of Molecular Sciences, 17(3/314). https://doi.org/10.3390/ijms17030314
• Chellat, M. F., Raguž, L., & Riedl, R. (2016). Targeting antibiotic resistance. Angewandte Chemie: International Edition, 55(23), 6600–6626. https://doi.org/10.1002/anie.201506818
• Chellat, M. F., Raguž, L., & Riedl, R. (2016). Antibiotikaresistenzen gezielt überwinden. Angewandte Chemie, 128(23), 6710–6738. https://doi.org/10.1002/ange.201506818
• Lanz, J., & Riedl, R. (2015). Merging allosteric and active site binding motifs : de novo generation of target selectivity and potency via natural-product-derived fragments. ChemMedChem, 10(3), 451–454. https://doi.org/10.1002/cmdc.201402478
• Todorova, M., Trendafilova, A., Danova, K., Simmons, L., Wolfram, E., Meier, B., Riedl, R., & Evstatieva, L. (2015). Highly oxygenated sesquiterpenes in Artemisia alba Turra. Phytochemistry, 110, 140–149. https://doi.org/10.1016/j.phytochem.2014.12.008
• Fischer, T., & Riedl, R. (2013). Strategic targeting of multiple water-mediated interactions : a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors. ChemMedChem, 8(9), 1457–1461. https://doi.org/10.1002/cmdc.201300278
• Höck, S., & Riedl, R. (2012). CyBy2 : a structure-based data management tool for chemical and biological data. Chimia, 66(3), 132–134. https://doi.org/10.2533/chimia.2012.132a
• Höck, S., & Riedl, R. (2012). chemf : a purely functional chemistry toolkit. Journal of Cheminformatics, 4(38). https://doi.org/10.1186/1758-2946-4-38
• Höck, S., Marti, R., Riedl, R., & Simeunovic, M. (2010). Thermal cleavage of the Fmoc protection group. Chimia, 64(3), 200–202. https://doi.org/10.2533/chimia.2010.200
• Heuser, S., Barrett, D. G., Berg, M., Bonnier, B., Kahl, A., Luz De La Puente, M., Oram, N., Riedl, R., Roettig, U., Gil, G. S., Seger, E., Steggles, D. J., Wanner, J., & Weichert, A. G. (2006). Synthesis of novel cyclopropylic sulfones and sulfonamides acting as glucokinase activators. Tetrahedron Letters, 47(16), 2675–2678. https://doi.org/10.1016/j.tetlet.2006.02.110
• Supekova, L., Pezacki, J. P., Su, A. I., Loweth, C. J., Riedl, R., Geierstanger, B., Schultz, P. G., & Wemmer, D. E. (2002). Genomic effects of polyamide/DNA interactions on mRNA expression. Chemistry & Biology, 9(7), 821–827. https://doi.org/10.1016/S1074-5521(02)00174-6
• Berkessel, A., & Riedl, R. (2000). Combinatorial de novo synthesis of catalysts : how much of a hit-structure is needed for activity? Journal of Combinatorial Chemistry, 2(3), 215–219. https://doi.org/10.1021/cc990073i
• Riedl, R., Tappe, R., & Berkessel, A. (1998). Probing the scope of the asymmetric dihydroxylation of polymer-bound olefins : monitoring by HRMAS NMR allows for reaction control and on-bead measurement of enantiomeric excess. Journal of the American Chemical Society, 120(35), 8994–9000. https://doi.org/10.1021/ja980183d
• Berkessel, A., & Riedl, R. (1997). Fluorescence reporters for phosphodiesterase activity. Angewandte Chemie: International Edition, 36(13-14), 1481–1483. https://doi.org/10.1002/anie.199714811
• Berkessel, A., & Riedl, R. (1997). Fluoreszenz-Reporter für Phosphodiesterase-Aktivität. Angewandte Chemie, 109(13-14), 1518–1520. https://doi.org/10.1002/ange.19971091313

Books, peer-reviewed

Riedl, R. (1998). Kombinatorische de novo Synthese von künstlichen Phosphorsäurediesterasen : Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln [Doctoral dissertation, Universität zu Köln]. http://kups.ub.uni-koeln.de/573/

Other publications

• Hess, S., Alonso, M. C., Brand, M., Lauw, S., Lindenmann, U., Göbel, K., Geurink, P. P., Fritz, G., Riedl, R., & Knobeloch, K.-P. (2025). A NanoBRET-based assay monitoring interactions in the USP18 signaling hub identifies the first cell-penetrant small molecule compromising USP18/ISG15 binding. bioRxiv. https://doi.org/10.1101/2025.03.30.646166
• Riedl, R. (2023). Development of small-molecule drugs for the treatment of leukemia. Transfer, 2023(1), 7. https://doi.org/10.21256/zhaw-30047
• Gall, F., Riedl, R., Sievers, M., Wermelinger, T., & Frasson, D. (2019). Durch die Natur inspiriertes Wirkstoffdesign. Transfer, 2019(1), 6. https://doi.org/10.21256/zhaw-30046
• Gall, F., Hohl, D., Frasson, D., Wermelinger, T., Mittl, P. R. E., Sievers, M., & Riedl, R. (2019). Cover picture : drug design inspired by nature : crystallographic detection of an auto‐tailored protease inhibitor template (Angew. Chem. Int. Ed. 12/2019). Angewandte Chemie: International Edition, 58(12), 3653. https://doi.org/10.1002/anie.201901671
• Riedl, R. (2014). Fighting the resistance. Horizon 2020 Projects, 2014(4), 130.
• Riedl, R. (2014). Nicht nur Metalloproteasen im Visier. Chemie Plus, 2014(4), 30–31.
• Riedl, R. (2013). Bridging the disciplines : cancer diagnostics & treatment. Pan European Networks: Science & Technology, 7, 240–241.
• Riedl, R., & Höck, S. (2013). CyBy² : clevere Handhabung strukturbasierter Datensätze. Transfer, 2013(1), 3. https://doi.org/10.21256/zhaw-2864
• Riedl, R. (2013). Organic chemistry : the heart and soul of drug discovery. International Innovation - EuroFocus, 18, 104–105.
• Riedl, R. (2013). Drug discovery through a chemist’s eyes. International Innovation - EuroFocus, 18, 103.
• Riedl, R., & Höck, S. (2012). Enhancing CyBy2 : visualization of structure activity relationships of large datasets. Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 13 September 2012.
• Riedl, R., & Brand, M. (2012). Synthese und medizinalchemische Optimierung von Tetrazyklinanaloga. À Jour: SVC - Chemie, Life Sciences & Biotechnologie, 2012(1), 10–11.
• Fischer, T., & Riedl, R. (2012). Design, synthesis and biological testing of novel MMP-inhibitors. Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 13 September 2012.
• Riedl, R., & Fischer, T. (2012). Structure based design and synthesis of novel MMP inhibitors. 19th EuroQSAR: «Knowledge Enabled Ligand Design», Vienna, Austria, 26-30 August 2012.
• Riedl, R., & Höck, S. (2011). CyBy2 : a modular rich client for the chemical and biological information management. Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R., Brand, M., & Sephton, M. (2011, September). Synthesis of tetracycline analogues. Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R., Fischer, T., Züger, P., & Brand, M. (2011, September). Structure based design and synthesis of novel MMP inhibitors. Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R., Höck, S., & Kunz, L. (2010, September). Profiling H-bond properties of fragments. Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 16 September 2010.
• Riedl, R., & Fischer, T. (2010, September 16). Fragment based scaffold hopping in drug discovery. Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 16 September 2010.

Oral conference contributions and abstracts

• Ehirchiou, D., Chirayath, T., Nasi, S., Chobaz, V., Riedl, R., Blatter, C., Germann, S., Brandenberger, A., Bommeli, E., Busso, N., & So, A. (2025). Positive allosteric modulators (PAMS) of cystathionine gamma lyase (CSE) increase hydrogen sulfide (H2S) and inhibit NLRP3 activation [Conference presentation]. Annals of the Rheumatic Diseases, 84(Supplement 1), 116–117. https://doi.org/10.1016/j.ard.2025.05.154
• Ehirchiou, D., Nasi, S., Chobaz, V., Riedl, R., Germann, S., Brandenberger, A., Bommeli, E., Blatter, C., Cirino, G., So, A., & Busso, N. (2025). Development of allosteric activators of cystathionine γ lyase (CSE) to augment hydrogen sulfide (H2S) and inhibit pathologic cartilage calcification [Conference presentation]. Annals of the Rheumatic Diseases, 84(Supplement 1), 112–113. https://doi.org/10.1016/j.ard.2025.05.149
• Ehirchiou, D., Nasi, S., Chobaz, V., Riedl, R., Blatter, C., Germann, S., Brandenberger, A., Bommeli, E., So, A., & Busso, N. (2025). Development of allosteric activators of cystathionine γ lyase (CSE) to augment hydrogen sulfide (H2S) and inhibit pathologic cartilage calcification [Conference presentation]. Osteoarthritis and Cartilage, 33, S452. https://doi.org/10.1016/j.joca.2025.02.660
• Riedl, R. (2024, October 23). Competencies in drug discovery. Tfz Innovation inside Pharma, Rotkreuz, Switzerland, 23 October 2024.
• Rimle, L., Pliatsika, D., Arnold, N., Kurth, S., Kaiser, M., Mäser, P., Kemmler, M., Adams, M., Riedl, R., & von Ballmoos, C. (2024). Molecular basis for leucinostatin A toxicity in mammals [Conference presentation]. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1865(149316). https://doi.org/10.1016/j.bbabio.2024.149316
• Riedl, R. (2024, June 6). Center of excellence for drug discovery. Competencies in Drug Discovery, Wädenswil, Switzerland, 6 June 2024.
• Bagatella, S., Haghayegh Jahromi, N., Monney, C., Polidori, M., Gall, F. M., Serra, F., Riedl, R., Engelhardt, B., & Oevermann, A. (2022). Microglia, rather than bacterial factors, mediate bovine neutrophil chemotaxis in neurolisteriosis [Conference presentation]. Journal of Comparative Pathology, 203, 61. https://doi.org/10.1016/j.jcpa.2023.03.073
• Abu Eid, S., Adams, M., Scherer, T., Torres-Gómez, H., Hackl, M. T., Riedl, R., Luger, A., & Fürnsinn, C. (2016). Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice [Conference presentation]. Diabetologia, 59(Suppl 1), S343. https://doi.org/10.1007/s00125-016-4046-9
• Abu Eud, S., Adams, M., Scherer, T., Torres-Gomez, H., Riedl, R., Luger, A., & Fürnsinn, C. (2015). Emodin, eine mutmaßlich anti-diabetisch wirksame Verbindung, beeinträchtigt die Glukosetoleranz adipöser Mäuse [Conference presentation]. Wiener Klinische Wochenschrift, 127(17-18), 735. https://doi.org/10.1007/s00508-015-0838-z
• Riedl, R. (2013, September 25). Tackling antibiotic resistance. ILMAC 2013, 19. Internationale Fachmesse Für Laboratoriums- Und Verfahrenstechnik, Messtechnik Und Automatik in Der Chemie (ILMAC), Basel, 24.-27. September 2013.
• Riedl, R. (2011, June). Drug discovery in the academic setting. 3. Wädenswiler Chemietag «Medizinalchemie - Fokus Wirkstoffentwicklung», Wädenswil, 16. Juni 2011.
• Riedl, R. (2010). Structure based drug design. Biotech in Medicine - Olten Meeting, Olten, 24. November 2010.
• Riedl, R. (2010, November). Structure activity relationship within a gene switching system. Symposium - Synthetic Biotechnology, Basel, 18.-19. November 2010.

Patents and patent applications

• Adams, Michael; Kemmler, Michael; Tobler, Andreas; Pliatsika, Dimanthi; Riedl, Rainer,

  2025.

  Compounds for treatment of cancer.

  Patent number WO2025172389 A1

  (2025-08-21)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2025172389A1

• Riedl, Rainer; Brand, Michael; Bommeli, Elias; Ochsenbein, Adrian; Riether, Carsten,

  2024.

  CD93 inhibitors.

  Patent number WO2024115637 A1

  (2024-06-06)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2024115637A1

• Adams, Michael; Kemmler, Michael; Pliatsika, Dimanthi; Riedl, Rainer,

  2024.

  Topical treatment of skin cancer using oligopeptides.

  Patent number WO2024033418 A1

  (2024-02-15)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2024033418A1

• Knechtle, Philipp; Gombert, Frank Otto; Riedl, Rainer; Lindenmann, Urs; Krebs, Walter; Wipfli, Dennis; Albert, Ina; Wegmann, Sandro; Schmid, Andrina,

  2023.

  Novel antifungal compounds.

  Patent number WO2023001905 A1

  (2023-01-26)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2023001905A1

• So, Alexander; Busso, Natalie; Nasi, Sonia; Brand, Michael; Gall, Flavio Max; Riedl, Rainer; Germann, Stefan,

  2022.

  Methods and compositions for treating conditions associated with hypermineralization.

  Patent number WO2022194953 A1

  (2022-09-22)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2022194953A1

• So, Alexander; Busso, Natalie; Nasi, Sonia; Brand, Michael; Gall, Flavio; Riedl, Rainer,

  2022.

  Methods and compositions for treating conditions associated with hypermineralization.

  Patent number EP4059498 A1

  (2022-09-21)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DEP4059498A1

• Adams, Michael; Kemmler, Michael; Riedl, Rainer; Pliatsika, Dimanthi; Imanidis, Georgios; Herzig, Susanne; Kaiser, Marcel; Mäser, Pascal,

  2022.

  Treatment of skin disorders.

  Patent number WO2022167656 A1

  (2022-08-11)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2022167656A1

• Agnello, Stefano; Adams, Michael; Kaiser, Marcel; Mäser, Pascal; Urban, Alexander; Raguz, Luka; Riedl, Rainer,

  2018.

  Antiprotozoal compounds.

  Patent number EP3345917 A1

  (2018-07-11)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DEP3345917A1

• Schneider, Peter; Riedl, Rainer; Tigges, Marcel; Gitzinger, Marc; Pieren, Michel; Levi, Assaf; Sephton, Mark; Schellhorn, Birgit; Züger, Patrik; Brand, Michael; Gygax, Daniel; Spies, Peter,

  2015.

  Composition for treatment of pathogens that are resistant to tetracyclines.

  Patent number EP2950793 A1

  (2015-12-09)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DEP2950793A1

• Weichert, Andreas Gerhard; Barrett, David Gene; Heuser, Stefan; Riedl, Rainer; Tebbe, Mark Joseph; Zaliani, Andrea,

  2011.

  Substituted arylcyclopropylacetamides as glucokinase activators.

  Patent number EP1585739 B1

  (2011-04-20)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DEP1585739B1

• Weichert, Andreas; Barrett, David; Heuser, Stefan; Riedl, Rainer; Tebbe, Mark; Zaliani, Andrea,

  2004.

  Heteroaryl compounds.

  Patent number WO2004063194 A1

  (2004-07-29)

  .

  Available from: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2004063194A1

Affiliations

Current Affiliations

ULTIMATE MEDICINE AG: Consulting
Consulting activities in the field of pharmaceutical drug discovery and drug development for the company Ultimate Medicine AG, founded and registered in Switzerland under company number CHE-438.939.011., Zürich
08 / 2024 - today

Past Affiliations

Czech Academy of Sciences: Consulting
Member of the evaluation commission of the Czech Academy of Sciences for the evaluation of the institute of organic chemistry and biochemistry, Prague, Prag
04 / 2025 - 12 / 2025

go back